Mandate

Vicore Pharma Holding acquires INIM Pharma

July 03, 2018

Vinge has advised the shareholders of INIM Pharma in connection with the sale of the company to Vicore Pharma Holding, which is listed on First North.

INIM Pharma develops a new local treatment of severe and unusual forms of lung disease such as idiopathic lung fibrosis. 

The acquisition is performed as an issue in kind corresponding to a dilution of 35.8 per cent. HealthCap VII LP owns 85 per cent of INIM and following the acquisition HealthCap VII LP will hold approximately 30.4 per cent of the shares in Vicore Pharma Holding.

The transaction is subject to customary closing conditions.

Vinge’s team consisted of Johan Winnerblad, Kristina Ekberg, Jesper Schönbeck, Rikard Lindahl and Malin Malm Waerme.
 

The Swedish rules on cabotage transport and posting will change on 2 and 21 February 2022

The Swedish government has decided on a number of new rules concerning cabotage transports, combined transports, transport customer responsibility for driving and rest times and posting of workers.
January 21, 2022

Vinge presents the Swedish chapter for the 2022 version of The Legal 500: Private Equity Country Comparative Guide

The guide provides an overview of the Swedish Private Equity market and the salient legislation in connection with PE transactions in Sweden.
January 11, 2022

The prohibition imposed by EU law on complying with secondary sanctions laid down by the United States against Iran may be relied on in civil proceedings

On Tuesday 21 December, the EU Court of Justice delivered its long-awaited judgment in the Bank Melli Iran case (Case C-124/20) on the interpretation of the EU Blocking Statute regarding compliance with third country sanctions. According to the Court, the prohibition imposed by EU law on complying with secondary sanctions laid down by the United States against Iran may be relied on in civil proceedings. Following the Court’s judgment, anyone seeking to terminate a contract with a person or business subject to US sanctions must thoroughly consider if the termination is motivated by other reasons than the existing sanctions and reflect on whether to apply to the Commission for a derogation from the Blocking Statute.
December 23, 2021